Infectious disease diagnostics comprises of various diagnostics technologies and platforms used by healthcare professionals to detect and diagnose diseases causing pathogens in human samples, including serum, blood, urine, throat swabs, and stool. It enables healthcare professionals for early diagnosis of the diseases and serves the patient population with better care management in less time and cost. With growing technological advancements, the infectious disease diagnosis platforms are increasingly becoming more useful to serve the patients with a more convenient, faster, and highly accurate diagnosis. It helps the end-users to provide a cost-effective treatment process to the patient population.
In 2019, the global infectious disease diagnostics market was valued at $9.11 billion. This market is projected to reach $12.88 billion by 2025 growing at a CAGR of 5.9% during the forecast period of 2019 to 2025.
Abbott Laboratories founded in 1888 and headquartered at Illinois, U.S., majorly engaged in the discovery, development, manufacturing, and sale of a comprehensive range of various healthcare products. The company develops its products with a wide array of product offerings in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals to meet the customer’s need. The company operates through its four reportable business segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products. The company offers the products for infectious disease diagnostics market through its diagnostic segments. The diagnostic product segments include core laboratory systems, molecular diagnostics systems, point of care systems, rapid diagnostics systems, and informatics and automation solutions.
The company has a wide geographic presence in countries such as Germany, Japan, India, Switzerland, Russia, France, Brazil, Italy, UK, the US, the Netherlands, Colombia, Vietnam, and other countries. The company operates through its 100 manufacturing facilities in 32 countries across the globe. The company has 28 manufacturing sites worldwide for developing diagnostic products.
Founded in 1969 and headquartered at Washington, D.C., U.S., Danaher primarily involved in designing, manufacturing, and marketing medical, professional, industrial, and commercial products and services for various end-users. The company operates through its four reportable business segments, namely, Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions. Danaher offers all its product and service offerings for infectious disease diagnostics market through its diagnostic business segment. The company’s diagnostic segments primarily offer analytical instruments, reagents, consumables, software and services to help hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The company has a wide geographic presence worldwide. The company’s research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 60 countries across the globe. The company is established its presence in the US, China, Germany, Japan, and other countries. Manufacturing facility for the diagnostic business segment is majorly located in North America, Europe, Asia, and Australia. The company sells its products through direct sales personnel and independent distributors.
Bio-Rad Laboratories, Inc.
Founded in 1952 and headquartered at Washington, D.C., U.S., Bio-Rad Laboratories, Inc. is primarily engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications. The company manufactures and supplies a wide array of products and systems to separate complex chemical and biological materials and to identify, analyze, and purify their components. The company operates through two reportable segments such as Life Science and Clinical Diagnostics. The company provides the products and services for infectious disease diagnostics market through its Clinical Diagnostics business segments. This segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.
The company has a broad geographic presence through its direct distribution channels and subsidiaries in over 35 countries across the globe.
Founded in 1963 and headquartered at Marcy-l’Étoile, France, bioMérieux primarily involved in providing various diagnostic solutions such as systems, reagents, and software to the private and hospital laboratories for the diagnosis of infectious diseases. The company offers various solutions such as antimicrobial resistance management, C. difficile infection management, HIV diagnostics & management, emergency department patient management, lab efficiency, and sepsis. The company is involved in the development and selling of its products for various business applications, namely, microbiology, immunoassays, molecular biology, industrial applications, and other lines.
The company has a diversified geographic presence in more than 150 countries through its 43 subsidiaries and a large distribution network. The company has its major presence in Americas, EMEA, and Asia Pacific countries.
F. Hoffmann-La Roche Ltd
Founded in 1896 and headquartered at Basel, Switzerland, F. Hoffmann-La Roche Ltd is a research-based healthcare company. The company is majorly engaged in creating innovative medicines and providing solutions for diagnostics tests to help the unmet need of the customers worldwide. The company operates through two major business segments, namely, pharmaceuticals and diagnostics. The company’s Diagnostic division consists of four business areas such as centralized and point of care solutions, molecular diagnostics, and diabetes care.
The company has its major geographic presence in North America, Europe, Asia, Latin America, Africa, Australia, and New Zealand. The company has 26 manufacturing sites and 30 R&D sites for its pharmaceutical and diagnostics business across the globe.
A report into the projected growth of the current Infectious Disease Diagnostics Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2025, it’s expected to have grown at a CAGR of 5.9%, reaching over $ 12.88 billion.
BD (Becton, Dickinson and Company)
Founded in 1897 and headquartered at New Jersy, U.S., BD (Becton, Dickinson and Company) is a global medical technology company. The company is primarily engaged in the development, manufacturing, and sale of a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company’s products are used by a wide array of end-users such as healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company primarily operates through three business segments, namely, BD Medical, BD Life Sciences, and BD Interventional. BD Interventional includes the product offerings of C.R. Bard which was acquired by BD in December 2017. The company provides its products for infectious disease diagnostics market through it BD Life Sciences business segment.
The company has a wide geographic distribution. The company manufactured and sold its product in the US, Europe, EMA, Greater Asia, Latin America, and Canada. The company has wide distribution network across the globe. It markets its products through independent distribution channels and directly to hospitals, other healthcare institution, and independent sales representatives.
Founded in 1896 and headquartered at Saluggia, Italy, DiaSorin S.p.A. develops, manufactures, and markets a comprehensive range of clinical areas such as infectious diseases, gastrointestinal infections, bone & mineral, endocrinology, hypertension, oncology, onco-haematology, and autoimmunity. The company provides testing kits and various technological platforms. The company provides its products at both private and hospital laboratories through its immunodiagnostics and molecular diagnostics segment.
The company has a wide geographic presence with 7 manufacturing facilities located in Europe, Africa, and the US. It has 24 companies and 4 branches in the 5 continents. The company distributes its products and platforms across the globe through its commercial subsidiaries.
Meridian Bioscience, Inc.
Founded in 1976 and headquartered at Ohio, US, Meridian Bioscience, Inc. is a fully integrated life science company primarily engaged in the development, manufacture, sale and distribution of diagnostic test kits, bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents. The company operates through its two primary reportable segments, namely, Diagnostics and Life Science. The company provides a broad spectrum of clinical diagnostics products testing platforms and technologies used to serve acute care hospitals, reference laboratories, outpatient clinics and physician office laboratories in over 70 countries across the world. The company majorly provides the products required in the infectious disease diagnostics market through its diagnostics business segment.
The company’s diagnostic business segment has a major geographic presence in the US, Italy, Japan, France, the U.K., Belgium, and Holland. The company operates through its subsidiaries located worldwide.
Founded in 1979 and headquartered at California, U.S., Quidel Corporation is a healthcare manufacturer majorly engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The diagnostic testing solutions provided by the companies are separated into four product categories such as rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The company serves a wide array of end users with its products including physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies and wellness screening centers.
The company sells its products in approximately 90 countries worldwide. The company has wide geographic presence across the globe through its subsidiaries. Some of its major subsidiaries are BioHelix Corporation (US), Quidel Germany, GmbH (Germany), Pacific Biotech, Inc. (US), Quidel China, Ltd. (China), Quidel Canada, ULC (Canada), and Quidel Ireland Limited (Ireland).
Thermo Fisher Scientific Inc.
Founded in 2006 and headquartered at Massachusetts, U.S., Thermo Fisher Scientific Inc., is a biotechnology company primarily engaged in accelerating life sciences research, solving complex analytical challenges, improves patient diagnostics, and increase laboratory productivity. The company operates through its four reportable business segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company’s Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products in order to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The laboratory Products and Services segment offer virtually everything needed for the laboratory.
The company provides the products for infectious disease diagnostics market through its Specialty Diagnostics segment. The company has established a wide geographic presence.
Authoritative Research on the Infectious Disease Diagnostics Market – Global Opportunity Analysis and Industry Forecast (2019-2025)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: